Thompson Peter A. 4

What Happened Peter A. Thompson, listed as a 10% owner of Corvus Pharmaceuticals (CRVS), received a derivative award for 15,000 shares on June 11, 2026. The award was granted at $0.00 (no cash paid) and is reported as an award/derivative (Form 4 code "A"). This was a grant of rights to acquire shares in the future, not a sale or open-market purchase.

Key Details

• Transaction date: 2026-06-11; filing date: 2026-06-15 (filed within the required two business days).
• Instrument: derivative award/option for 15,000 shares reported at $0.00.
• Shares owned after transaction: not specified in the filing; reporting person disclaims beneficial ownership per footnote (see below).
• Footnote F1: Award vests and becomes exercisable 100% on the earlier of (i) the first anniversary of the grant or (ii) the 2027 Annual Meeting, subject to continued service.
• Footnote F2: Thompson is obligated to transfer any securities or economic benefit from this award to OrbiMed Advisors LLC and OrbiMed Capital GP V LLC for the benefit of OrbiMed Private Investments V, LP; he disclaims beneficial ownership except for any pecuniary interest.

Context This filing reports a grant of an option/award (a derivative), not an immediate exercise or sale — no shares were sold and no cash was exchanged at grant. The footnotes indicate the award is intended to benefit an institutional investor (OrbiMed Private Investments V, LP), and the reporting person disclaims beneficial ownership. Grants like this are commonly part of compensation or investment arrangements and do not, by themselves, indicate immediate buying or selling in the market.